TR199901703T2 - Siklooksijenaz-2 inhibitörlerini anti-anjiyojenik ajanlar olarak kullanma yöntemi. - Google Patents

Siklooksijenaz-2 inhibitörlerini anti-anjiyojenik ajanlar olarak kullanma yöntemi.

Info

Publication number
TR199901703T2
TR199901703T2 TR1999/01703T TR9901703T TR199901703T2 TR 199901703 T2 TR199901703 T2 TR 199901703T2 TR 1999/01703 T TR1999/01703 T TR 1999/01703T TR 9901703 T TR9901703 T TR 9901703T TR 199901703 T2 TR199901703 T2 TR 199901703T2
Authority
TR
Turkey
Prior art keywords
cyclooxygenase
inhibitors
angiogenic agents
angiogenic
agents
Prior art date
Application number
TR1999/01703T
Other languages
English (en)
Inventor
L. Masferrer Jaime
Raz Amiram
Original Assignee
G.D. Searle & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.D. Searle & Co. filed Critical G.D. Searle & Co.
Publication of TR199901703T2 publication Critical patent/TR199901703T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Bu bulus siklooksijenaz-2 inhibitörlerinin veya türevlerinin anjiyojenik bozukluklarin önlenmesi ve tedavisinde kullanimina iliskindir.
TR1999/01703T 1996-11-19 1997-11-19 Siklooksijenaz-2 inhibitörlerini anti-anjiyojenik ajanlar olarak kullanma yöntemi. TR199901703T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19

Publications (1)

Publication Number Publication Date
TR199901703T2 true TR199901703T2 (tr) 2000-07-21

Family

ID=21859277

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01703T TR199901703T2 (tr) 1996-11-19 1997-11-19 Siklooksijenaz-2 inhibitörlerini anti-anjiyojenik ajanlar olarak kullanma yöntemi.

Country Status (19)

Country Link
EP (1) EP0941080A2 (tr)
JP (1) JP2001505564A (tr)
KR (1) KR20000053362A (tr)
CN (1) CN1247470A (tr)
AU (1) AU730211B2 (tr)
BR (1) BR9713522A (tr)
CA (1) CA2270469C (tr)
CZ (1) CZ176899A3 (tr)
ID (1) ID21979A (tr)
IL (1) IL129604A (tr)
NO (1) NO992309L (tr)
NZ (1) NZ335853A (tr)
PL (2) PL194717B1 (tr)
RO (1) RO118566B1 (tr)
RU (1) RU2268716C2 (tr)
SK (1) SK59999A3 (tr)
TR (1) TR199901703T2 (tr)
UA (1) UA70294C2 (tr)
WO (1) WO1998022101A2 (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
AU2713500A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2363590A1 (en) * 1999-03-10 2000-09-14 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor
PT1206256E (pt) * 1999-07-29 2005-09-30 Amgen Inc Terapia de combinacao utilizando pentafluorobenzenosulfonamida e compostos de platina
WO2001087287A2 (en) * 2000-05-19 2001-11-22 Applied Research Systems Ars Holding N.V. Use of pyrazole derivatives for treating infertility
US6822001B2 (en) 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
JP2006503812A (ja) * 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−２阻害薬との組み合わせ
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
RU2475257C1 (ru) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Средство для повышения адаптируемости организма к экстремальным условиям
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9422447U1 (de) * 1993-01-15 2002-10-17 G D Searle Llc Chicago 3,4-Diarylthiophene und Analoga davon, sowie deren Verwendung als entzündungshemmende Mittel
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
DK0923933T3 (da) * 1993-11-30 2002-10-21 Searle & Co Substituerede pyrazolyl-benzensulfonamider til anvendelse ved behandling af inflammation
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
DE69529690T2 (de) * 1994-12-21 2003-11-13 Merck Frosst Canada Inc Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Also Published As

Publication number Publication date
KR20000053362A (ko) 2000-08-25
PL191793B1 (pl) 2006-07-31
CA2270469C (en) 2007-04-10
NO992309D0 (no) 1999-05-12
EP0941080A2 (en) 1999-09-15
PL194717B1 (pl) 2007-06-29
JP2001505564A (ja) 2001-04-24
SK59999A3 (en) 2000-01-18
AU730211B2 (en) 2001-03-01
ID21979A (id) 1999-08-19
BR9713522A (pt) 2000-03-21
PL333370A1 (en) 1999-12-06
CA2270469A1 (en) 1998-05-28
AU7298298A (en) 1998-06-10
IL129604A0 (en) 2000-02-29
IL129604A (en) 2004-08-31
CZ176899A3 (cs) 1999-10-13
CN1247470A (zh) 2000-03-15
WO1998022101A2 (en) 1998-05-28
RU2268716C2 (ru) 2006-01-27
WO1998022101A3 (en) 1998-06-25
NO992309L (no) 1999-05-12
RO118566B1 (ro) 2003-07-30
UA70294C2 (en) 2004-10-15
NZ335853A (en) 2002-02-01

Similar Documents

Publication Publication Date Title
TR199902545T2 (tr) Kalp damar hastaliklarinin önlenmesinde siklooksijenaz-2 inhibitörlerini kullanma yöntemi
TR199901703T2 (tr) Siklooksijenaz-2 inhibitörlerini anti-anjiyojenik ajanlar olarak kullanma yöntemi.
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE173630T1 (de) Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
TR199801390T2 (tr) Tromboz tedavisinde kullanilacak pihtilasmayi önleyici maddeler
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DK0705100T3 (da) Terapeutiske substituerede guanidiner
HRP20050572A2 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
TR199802704T2 (tr) HIV tedavisinde Vx478, Zidovüdin, FTC ve/veya 3TC içeren kombinasyonlarin kullanimi.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE69423533D1 (de) Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
DK0885005T3 (da) Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd
TR199801988T2 (tr) Kalp yetmezliginin endotelin antagonistleri ile tedavisi için yöntem.
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
NO20032597D0 (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
IL139144A0 (en) Mycobacterial inhibitors
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
TR199802703T2 (tr) HIV tedavisinde Vx478, Zidovüdin, ve/veya 1592U89 içeren kombinasyonlarin kullanimi.
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma